Changes in circulatory load, inflammation and end-organ damage In a linear regression model adjusted for baseline value, treatment allocation and interaction between treatment and covariates, at 52 weeks, the reductions in estimated BV with tirzepatide were correlated with decreases in systolic BP (slope 6.12, 95% CI 3.47 to 8.78
Many compounded tirzepatide formulations already include B12 for this reason
There is not enough evidence to suggest it is safe to use
Due to its shorter sequence, TB-500 offers enhanced metabolic stability and amenability to synthetic optimization compared to the parent protein
The study is also limited because of its use of clinical electronic health record data, which could have resulted in delayed times and under-reported adverse events
Tirzepatides dual agonist action not only improves glucose control but also promotes significant weight loss, as demonstrated in clinical trials